Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTangible Book ValueTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewGenIvf (NIVF) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for NewGenIvf (NIVF) over the last 4 years, with Q3 2025 value amounting to $35558.4 billion.

  • NewGenIvf's Liabilities and Shareholders Equity changed N/A to $35558.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $35558.4 billion, marking a year-over-year change of. This contributed to the annual value of $3.6 million for FY2024, which is 2026.42% down from last year.
  • As of Q3 2025, NewGenIvf's Liabilities and Shareholders Equity stood at $35558.4 billion.
  • In the past 5 years, NewGenIvf's Liabilities and Shareholders Equity ranged from a high of $35558.4 billion in Q3 2025 and a low of $2.9 million during Q4 2022
  • Its 4-year average for Liabilities and Shareholders Equity is $7111.7 billion, with a median of $4.5 million in 2023.
  • In the last 5 years, NewGenIvf's Liabilities and Shareholders Equity soared by 5445.95% in 2023 and then plummeted by 2026.42% in 2024.
  • Quarter analysis of 4 years shows NewGenIvf's Liabilities and Shareholders Equity stood at $2.9 million in 2022, then skyrocketed by 54.46% to $4.5 million in 2023, then fell by 20.26% to $3.6 million in 2024, then soared by 993877438.47% to $35558.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $35558.4 billion for Q3 2025, versus $14.8 million for Q2 2025 and $3.6 million for Q4 2024.